– Utrecht (the Netherlands) & Cambridge (Massachusetts - US) - Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), announced…
– Utrecht, The Netherlands & Tokyo, Japan - AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, and Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin), a global specialty pharmaceutical company that strives to create new value through the…
– First Noema clinical trial, with asset in-licensed from Roche with strong clinical safety package Noema advancing potentially life-changing therapeutics for patients without satisfactory treatments Basel – Noema Pharma, a Swiss-based clinical stage company targeting orphan…
– San Francisco (California, US) & Cambridge (Massachusetts, US) – Spire Health, the leading provider of respiratory remote patient monitoring (RPM), today announced the closing of a $38 million equity financing, led by Gilde Healthcare Partners along with a leading global medtech strategic…
– LAVA’s first-in-class gamma-delta bsTCE to be evaluated as a treatment for chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia Utrecht (the Netherlands) & Philadelphia (US) – Gilde Healthcare portfolio company LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology…
– Utrecht (the Netherlands) & Copenhagen (Denmark) – Gilde Healthcare portfolio company Adcendo, a biotech company developing innovative antibody-drug conjugates (ADCs) for the treatment of underserved cancers, announces today the appointment of Michael Pehl as Chief Executive Officer…
– Utrecht (the Netherlands) & Mont-Saint-Guibert (Belgium) – Gilde Healthcare portfolio company Nyxoah SA, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today started trading on NASDAQ. Gross…
– Utrecht (the Netherlands) & Minneapolis (USA) – Gilde Healthcare portfolio company CVRx Inc., a commercial-stage medical device company focused on innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, announced on Tuesday, June 29,…
– Utrecht (the Netherlands) & Mont-Saint-Guibert (Belgium) – Nyxoah, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the BETTER SLEEP trial reached its primary safety and…
– Keensight Capital, one of the principal private equity managers dedicated to pan-European Growth Buyout1 investments, has reached an agreement to invest alongside management in Symeres, a leading European drug discovery Contract Research Organization (CRO) and Contract Development…
– Northern European integrated drug development consultancy aims to further expand service offering and geographical footprint Utrecht (the Netherlands) and Copenhagen (Denmark) – Gilde Healthcare, a specialized healthcare investor, and KLIFO A/S, a leading Northern European drug…
– Utrecht (the Netherlands) and Copenhagen (Denmark) – ADCendo ApS (“Adcendo”), a Danish biopharmaceutical company developing antibody-drug conjugates (ADCs) for the treatment of cancers, today announced the successful closing of a €51 million ($62 million) Series A financing. The global…
– Investment to support the global expansion of leading manufacturer of precision medical components and devices Utrecht (the Netherlands) and Freienstau – The Private Equity fund of Gilde Healthcare, a specialist healthcare investor, has acquired Acti-Med, a leading international…
– Utrecht and Eindhoven (the Netherlands) – Gilde Healthcare, a specialized healthcare investor with €1.4 billion under management, announces its investment in dental chain Tandarts Today. With this acquisition, Gilde Healthcare enters the Dutch Dental Care Market with its attractive…
– Utrecht (the Netherlands) and Mannheim (Germany) – RAD-x, the leading European diagnostic imaging practice operator and portfolio company of Gilde Healthcare Private Equity, is adding Medizin Center Bonn (MCB) to its group. MCB provides cutting-edge premier nuclear medicine- and radiology…
– Amsterdam, the Netherlands – LUMICKS, a leading, next generation life science tools company that develops highly innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, announced the completion of a $93 million Series D preferred share financing. The funding…
– Utrecht, the Netherlands – Gilde Healthcare, a specialized healthcare investor with $1.8 billion under management, today announced that its portfolio company, LAVA Therapeutics (Nasdaq: LVTX), has successfully achieved pricing of its Nasdaq initial public offering (IPO), expected…
– Amphista Therapeutics today announced the closing of a $53 million (£38 million) Series B financing round from an investor syndicate co-led by Gilde Healthcare. The proceeds will be used to accelerate the company’s growing pipeline of potent and selective bifunctional molecules, known as ‘Amphistas’ to the clinic and to extend its proprietary TPD platform.
– IRVINE, California US – Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, last week announced that…
– Zeewolde, the Netherlands – Ace Pharmaceuticals (Ace), a specialized pharmaceutical company in medical need medicines, strengthens its shareholders base with the addition of Gilde Buy Out Partners and Gilde Healthcare. Founded in 1990 and based in Zeewolde, Ace focuses on the development,…
– Utrecht, The Netherlands and Philadelphia, USA – LAVA Therapeutics B.V., an early clinical-stage biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced the appointment of Dr. Kapil Dhingra as chairman…
– Cambridge, UK and Indianapolis, US – Acacia Pharma (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or…
– Utrecht (The Netherlands) – Nyxoah SA (Euronext: NYXH) (“Nyxoah” or the “Company”), a health-technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), today announces the Company has signed an exclusive…
– Approximately 40 million procedures take place annually in the US that require the use of procedural sedation BYFAVO is the second Acacia Pharma product approved and launched in the US in the last year and extends its portfolio of new products targeting unmet needs in anesthesia Cambridge…
– Utecht (The Netherlands) – Nyxoah SA (Euronext: NYXH) (“Nyxoah” or the “Company”), a health-technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), today announces the Company has received CE…
– This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge (United Kingdom) and Utrecht (the Netherlands) – Acacia Pharma Group plc (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused…
– Utrecht (the Netherlands) – RAD-x is welcoming Radiologisches Zentrum Lahnstein (“RZL”) in its group. Radiologisches Zentrum Lahnstein is a provider of diagnostic imaging services in the region Koblenz, Germany. Its three radiologists and almost 30 staff serve the community in…
– First patients with COVID-19 enrolled in the REVIVAL Phase III study COVID-19 patients with sepsis-associated acute kidney injury will be included in an exploratory cohort in the pivotal trial enrolling up to 1,600 SA-AKI patients overall RVO, an agency of the Dutch Ministry of…
– Marseille (France) - Utrecht (the Netherlands) – Volta Medical, a French-based HealthTech startup, pioneering novel artificial intelligence (AI) algorithms to treat cardiac arrythmias, today announced that it has successfully raised an 28 million USD financing round led by Gilde Healthcare.…